BioX­cel touts healthy vol­un­teer da­ta for neu­ro ther­a­py; Io­n­is, Chi­nook part­ner on rare kid­ney dis­ease

BioX­cel Ther­a­peu­tics re­port­ed some new healthy vol­un­teer da­ta that it’s tout­ing as pos­i­tive.

The biotech said in a press re­lease Tues­day that its ex­per­i­men­tal BX­CL501 ther­a­py as an ad­junct for ma­jor de­pres­sive dis­or­der proved safe and tol­er­a­ble in a Phase Ib mul­ti­ple-as­cend­ing dose tri­al, re­sults that al­low re­searchers to se­lect a dose for Phase II. The max­i­mum tol­er­at­ed dose was not at­tained, CMO Robert Risinger said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER